Stocksigma LogoStocksigma Logo

Mangalam Drugs & Organics Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

■ Revenue: 7,939 (+61.2% YoY | +39.0% QoQ) ■ EBITDA: -115 (+63.1% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -1.5 (+488 bps YoY | Profit to Loss QoQ) ■

Mangalam Drugs & Organics Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

Mangalam Drugs & Organics Ltd · Outcome · 06 Nov 2026, 12:01 am

Mangalam Drugs & Organics Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 7,939 (+61.2% YoY | +39.0% QoQ) ■ EBITDA: -115 (+63.1% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -1.5 (+488 bps YoY | Profit to Loss QoQ) ■ PAT: -721 (+1.9% YoY | +5.6% QoQ) ■ EPS (INR): -4.55 (+1.9% YoY | +5.8% QoQ)

Original exchange filing (PDF)

More announcements from Mangalam Drugs & Organics Ltd

All Mangalam Drugs & Organics Ltd announcements